Acumen PharmaceuticalsvsAmgen

ABOS and AMGN stock compared: price, dividend, valuation and results, from SEC filings.

ABOS

Acumen Pharmaceuticals, Inc.

$0.19

Value $13M

-3.11%
ABOS's page

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

Acumen Pharmaceuticals (ABOS) has a market value of $13M and Amgen (AMGN) $235B. Over the last year, with dividends, ABOS moved -87.9% and AMGN +31.5%. Dividend yield: ABOS none, AMGN 2.31%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABOS$13M

    AMGN$235B

    AMGN is 17,437 times ABOS

  • Revenue, 12 months

    ABOS–

    AMGN$38.9B

  • Net income, 12 months

    ABOS-$104M

    AMGN$9.4B

  • Operating margin

    ABOS–

    AMGN32.4%

  • ROIC

    ABOS-96.3%

    AMGN16.2%

    112.5 points apart

  • P/E

    ABOS–

    AMGN25.0

  • Dividend yield

    ABOS0.0%

    AMGN2.3%

    2.3 points apart

  • 5-year return

    ABOS-98.1%

    AMGN+146.3%

    244.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABOS-98.1%

AMGN+146.3%

010020020222023202420252026
Returns by period
PeriodABOSWith dividendsAMGNWith dividends
1 year since November 19, 2025-87.9%Price -87.9%+31.5%Price +27.2%
3 years since November 20, 2023-92.1%-57.0% a yearPrice -92.1%+79.2%+21.5% a yearPrice +64.2%
5 years since November 19, 2021-98.1%-54.8% a yearPrice -98.1%+146.3%+19.8% a yearPrice +111.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABOSAcumen PharmaceuticalsAMGNAmgen

Valuation

ABOSAMGN
Valuation
Price$0.19$435.64
Market value$13M$235B
Enterprise value (EV)–$276B
P/E–25.0
P/E, 5-year median–23.0
P/B0.416.4
EV/EBIT–21.9
Free cash flow yield–4.1%

Results and growth

ABOSAMGN
Results and growth
Revenue, 12 months–$38.9B
Net income, 12 months-$104M$9.4B
Free cash flow, 12 months-$88M$9.6B
Earnings per share, 12 months-$1.54$17.25
Revenue growth, year on year–10.0%
Revenue growth a year, past–+7.6%over 5 years
EPS growth a year, past–+2.9%over 5 years

Margins and returns on capital

ABOSAMGN
Margins and returns on capital
Gross margin–70.9%
Operating margin–32.4%
Net margin–24.1%
ROIC-96.3%16.2%
ROE-151.6%87.8%

Balance sheet

ABOSAMGN
Balance sheet
Cash$79M$13.2B
Total debt–$54.0B
Net debt / EBITDA–2.3
Interest cover-29.1×4.8×

Dividends and buybacks

ABOSAMGN
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$10.08
Dividend growth a year, past–+8.1%over 5 years
Buyback yield––
Shareholder yield–2.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABOS or AMGN

Didn't find what you were looking for?

Ask us
Which is bigger, Acumen Pharmaceuticals or Amgen?

By market value, Amgen ($235B) is about 17,437.3 times Acumen Pharmaceuticals ($13M), at today's prices.

How did ABOS and AMGN stock do over the last 5 years?

Since November 19, 2021, ABOS's price moved -98.1% and AMGN's +111.4%. With dividends: ABOS -98.1% (-54.8% a year), AMGN +146.3% (+19.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABOS or AMGN?

The dividend yield at today's price is none for Acumen Pharmaceuticals and 2.31% for Amgen. Over the last twelve months they paid – and $10.08 per share.

Which is the better investment, Acumen Pharmaceuticals or Amgen?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.